Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen


During the 4 days of the Congress, about 6,000 participants from around the world: psychiatrists, neurobiologists and neurologists will discuss the most important scientific reports on diagnostics and brain treatment, from baseline studies to clinical development.

During the Congress, the Clinical Department representatives will present the results in a poster session which will take place on 8 September 2019.

Poster: Safety and pharmacokinetic study of inhaled Esketamine after a multiple dose in healthy volunteers

Presented by: Sylwia Janowska

Poster number: P.164